Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To provide access to nusinersen to eligible patients with Infantile-onset Spinal Muscular Atrophy (SMA) (consistent with Type 1) to address a high-unmet medical need.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies

NCT02594124

Spinal Muscular Atrophy

COMPLETED PHASE3

A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)

NCT04488133

Muscular Atrophy, Spinal

COMPLETED PHASE4

Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy

NCT04089566

Muscular Atrophy, Spinal

COMPLETED PHASE3

A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).

NCT02462759

Spinal Muscular Atrophy

TERMINATED PHASE2

Effect of Nusinersen on Adults With Spinal Muscular Atrophy

NCT03878030

Adult Spinal Muscular Atrophy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The nusinersen expanded access program (EAP) is available at approved treatment centers in select territories.

A doctor must decide whether nusinersen treatment is appropriate for each patient, based on the patient's medical history and program eligibility criteria. A full list of participating treatment centers is provided in the 'Contacts and Locations' section of this listing, and is regularly updated.

Following local approval and official reimbursement of nusinersen in each territory, the EAP will close and patients will transfer to commercially available drug.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infantile-onset Spinal Muscular Atrophy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nusinersen

Administered by intrathecal injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ISIS 396443 BIIB058 Spinraza

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or compound heterozygote.
* Onset of clinical signs and symptoms at ≤ 6 months (180 days) of age, consistent with infantile onset, Type I SMA
* Patient whose care in the opinion of the treating physician meets, and is expected to continue to meet, the guidelines set out in the 2007 Consensus Statement for Standard of Care in SMA

Exclusion Criteria

* Patient is qualified to participate in an ongoing clinical trial with nusinersen
* Participation in a prior nusinersen study
* Previous exposure to nusinersen
* History of brain or spinal cord disease that would interfere with the LP procedures or CSF circulation
* Presence of implanted shunt for the drainage of CSF or implanted CNS catheter
* Previous or current participation in a clinical trial with an investigational gene therapy for SMA
* Participation in a study with an investigational therapy for SMA within 6 months or five half-lives of the investigational drug, whichever is the longer, prior to the first dose of nusinersen.

Eligible Sex

ALL

Accepts Healthy Volunteers

No